

Info Sheet for Technical description

No.0013

Organization

* Mandatory fields

Name of Organization*	TWOCELLS COMPANY, LIMITED	
Address, City, States, Zip, Country*	OTANI Bldg. 2F, 1-6-10 Deshio, Minami-ku, Hiroshima City, 734-0001, Japan	
URL	https://www.twocells.com/	
Brief Descriptions of Organization* (Approx. 100 words)	We are developing allogeneic regenerative medical products using serum-free media developed in-house. We hold patents on large-scale culture of mesenchymal stem cells using serum-free media, adaptation to many diseases, and formulations.	
Contact address	Name*	Masaya Matsumoto
	Department* / Position	Representative Director
	E-mail* / TEL	e-mail:matsumoto-masaya@twocells.com tell: +81-82-256-2451

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines
- ☒ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B)
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

→ Please see **Sheet [A]**→ Please see **Sheet [B]**→ Please see **Sheet [C]**

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☒ Yes
- ☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☒ Series B
- ☐ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	
☐ No	

Filled in by*

Date*

Masaya Matsumoto
23-Jul-25

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0013

* Mandatoty fields

Title***gMSC (guaranteed Mesenchymal Stem Cell) @1 for symptomatic knee cartilage defects and osteochondritis dissecans****Development Phase***

- | | | |
|---|--|--|
| ☐ Basic Research | ☐ Drug Discovery | ☐ Pre-Clinical |
| ☐ Clinical Trial (Phase I) | ☐ Clinical Trial (Phase II) | ☒ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Diesease Area*

- | | | |
|---|---|---|
| ☐ Cancer | ☐ Central nervous system | ☐ Ophthalmology |
| ☒ Musculoskeletal | ☐ Endocrine / Metabolism | ☐ Cardiovascular |
| ☐ Urogenital | ☐ Digestive organ | ☐ Blood |
| ☐ Infection | ☐ Dermatology | ☐ Immunity |
| ☐ Otolaryngology | ☐ Respiratory | ☐ Others |

Description*

TWOCELLS COMPANY, LIMITED had been developing gMSC1 as cartilage regeneration of knee cartilage defect and osteochondritis dissecans until 2024, but the project was discontinued. As of June 2025, development has resumed following a new partnership.

The details of gMSC[®]1 clinical study information as below(excerpt from JRCT:<https://jrct.mhlw.go.jp/pages/en-detail/81054/jRCT/3>).

Study Title: A Randomized, Open-Label, Controlled, Phase III Trial Comparing guaranteed Mesenchymal Stem Cell 1 (gMSC1) versus Microfracture (MFx) in Patients with Symptomatic Articular Cartilage Defects or Osteochondritis Dissecans in the Knee.

Stundy Design:The objective is to compare the efficacy and safety of gMSC1 versus MFx, as standard treatment, in patients with symptomatic articular cartilage defects including osteochondritis dissecans in the knee.

Primary end point: safety and efficacy(1. Histological evaluation of cartilage repair at 52 weeks after gMSC1 transplantation or MFx, 2. Knee Injury and Osteoarthritis Outcome Score at 52 weeks after gMSC1 transplantation or MFxAssesment and observation)

Secondary endpoints:safety, efficacy(1. Anatomical evaluation of subchondral bone at 52 weeks after gMSC1 transplantation or MFx, 2. EuroQol 5 Dimension, 3. Time to Treatment Failure, etc.

Assesment and observation

Status:Terminated

Filled in by*

Masaya Matsumoto

Date*

23-Jul-25